Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development
Authors:
Open Access
- 1 July 2016
- journal article
- review article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 44 (7) , 934-943
Abstract
Childhood cancer represents more than 100 rare and ultra-rare diseases with an estimated 12,400 new cases diagnosed each year in the US, and as such this much smaller patient population has led to pediatric oncology drug development lagging behind that for adult cancers. Developing drugs for pediatric malignancies also brings with it a number of unique trial design considerations including flexible enrolment approaches, age appropriate formulation, acceptable sampling schedules, and balancing the need for age-stratified dosing regimens given the smaller patient populations. The regulatory landscape for pediatric pharmacotherapy has evolved with US FDA legislation such as the FDA Safety and Innovation Act, 2012. In parallel, the regulatory authorities have recommended the application of physiologically-based PK modeling (PBPK) for example, in the recently issued FDA Strategic Plan for Accelerating the Development of Therapies for Pediatric Rare Diseases. PBPK modeling provides a quantitative and systems-based framework that allows the impact of intrinsic and extrinsic factors on drug exposure to be modeled in a mechanistic fashion. The application of PBPK modeling in drug development for pediatric cancers is relatively nascent, with several retrospective analyses of cytotoxic therapies, and latterly for targeted agents such as obatoclax and imatinib. More recently, we have employed PBPK modeling in a prospective manner to inform the first pediatric trials of pinometostat and tazemetostat in genetically defined populations, MLL-r leukemia and INI-1 deficient sarcomas, respectively. In this review, we evaluate the application of PBPK modeling in pediatric cancer drug development and discuss the important challenges that lie ahead in this field.Keywords
This publication has 54 references indexed in Scilit:
- Inter-individual variation in midazolam clearance in childrenArchives of Disease in Childhood, 2014
- Drug discovery in paediatric oncology: roadblocks to progressNature Reviews Clinical Oncology, 2014
- Paediatric oral biopharmaceutics: Key considerations and current challengesAdvanced Drug Delivery Reviews, 2014
- Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitorBiopharmaceutics & Drug Disposition, 2014
- Summary of the National Institute of Child Health and Human Development–Best Pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop–Pediatric Biopharmaceutics Classification System Working GroupClinical Therapeutics, 2012
- Physiologically Based Pharmacokinetic (PBPK) Modeling in ChildrenClinical Pharmacology & Therapeutics, 2012
- Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult ExperienceBlood, 2011
- Ontogeny of Dextromethorphan O- and N-demethylation in the First Year of LifeClinical Pharmacology & Therapeutics, 2007
- Prediction of Cytochrome P450-Mediated Hepatic Drug Clearance in Neonates, Infants and ChildrenClinical Pharmacokinetics, 2006
- Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugsBritish Journal of Clinical Pharmacology, 2004